Oncology Research

Papers
(The TQCC of Oncology Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Galectins dysregulation: A way for cancer cells to invade and pervade47
Has_circ_0000069 expression in breast cancer and its influences on prognosis and cellular activities35
Inhibition of apoptosis-regulatory protein Siva-1 reverses multidrug resistance in gastric cancer by targeting PCBP134
Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer29
Survival and comorbidities in lung cancer patients: Evidence from administrative claims data in Germany28
Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations27
Long noncoding RNA TFAP2A AS1 exerts promotive effects in non small cell lung cancer progression via controlling the microRNA 548a 3p/CDK4 axis26
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma26
System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer25
A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells24
The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway21
Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis19
Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas18
Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data18
Identification of lncRNAs associated with the progression of acute lymphoblastic leukemia using a competing endogenous RNAs network17
Is autophagy induction by PARP inhibitors a target for therapeutic benefit?16
Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer14
The role of LIN28B in tumor progression and metastasis in solid tumor entities14
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance13
Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study13
Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma13
Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells12
YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells12
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials11
Deoxynortryptoquivaline: A unique antiprostate cancer agent11
The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells11
0.050205945968628